Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

Market Cap	545.02B
Revenue (ttm)	15.05B
Net Income (ttm)	-6.93B
Shares Out	48.02M
EPS (ttm)	-174.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,218
Average Volume	186,045
Open	11,480
Previous Close	11,540
Day's Range	11,320 - 11,560
52-Week Range	11,320 - 22,700
Beta	1.07
RSI	32.23
Earnings Date	Mar 17, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 54
• Stock Exchange: KOSDAQ
• Ticker Symbol: 048410

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.